journal article·2019-12-04Open access

Alkannin restrains oral squamous carcinoma cell growth, migration and invasion by regulating microRNA-9/RECK axis

Yulong Mao, Weiwei Zhang, Ronghe Zhang, Jinhua Zuo

Abstract

Alkannin (ALK) has anti-inflammatory and anti-tumour activities. We tried to probe the underlying functions of ALK in oral squamous carcinoma (OSCC) cells growth, migration and invasion. OSCC cells viability was investigated after treatment with ALK. Then, BrdU, flow cytometry, Western blot and Transwell assays were executed to appraise proliferation, apoptosis, migration and invasion in OSCC cells with ALK stimulation. The biological functions of miR-9 were explored after miR-9 mimic/inhibitor transfection. The relevance of RECK and miR-9 was predicated by dual luciferase activity assay. JAK1/STAT3 and PI3K/AKT pathways were estimated by Western blot. Tumour formation in vivo was executed by xenograft tumours assay. We found that ALK restrained cell proliferation, facilitated apoptosis, repressed migration and invasion also interdicted JAK1/STAT3 and PI3K/AKT pathways in CAL-27 and SCC-9 cells. miR-9 expression was upgraded in OSCC tissues but decreased in OSCC cells along with ALK administration; meanwhile, overexpressed miR-9 inverted the influences of ALK in OSCC cells growth, migration and invasion. RECK was predicated as a novel target gene of miR-9, and overexpressed RECK hindered JAK1/STAT3 and PI3K/AKT pathways in OSCC cells. ALK prohibited tumour formation in vivo. In conclusion, ALK restrained OSCC cells growth, migration and invasion via adjusting miR-9/RECK axis.HighlightsALK restrains cell growth, migration and invasion in OSCC cells;miR-9 is enhanced in OSCC tissues but is repressed by ALK in OSCC cells;miR-9 inverts the repressive effect of ALK on CAL-27 and SCC-9 cells;RECK is a novel target of miR-9;ALK or RECK hinders JAK1/STAT3 and PI3K/AKT pathways in CAL-27 and SCC-9 cells;ALK prohibits tumour formation in vivo.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · MicroRNA in disease regulation · Cytokine Signaling Pathways and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Oral and Maxillofacial Surgery, Binzhou Medical University Hospital

Department of Orthodontics, Binzhou Medical University Hospital

References (40)

Show source-provided references
1. 10.1097/MOO.000000000000023710.1097/MOO.0000000000000237 ↗
2. 10.1002/hed.2458910.1002/hed.24589 ↗
3. 10.1155/2017/728565610.1155/2017/7285656 ↗
4. 10.1016/j.oraloncology.2012.03.01310.1016/j.oraloncology.2012.03.013 ↗
5. 10.1016/j.bjoms.2017.01.00310.1016/j.bjoms.2017.01.003 ↗
6. 10.1186/s13014-017-0910-010.1186/s13014-017-0910-0 ↗
7. 10.1001/jamaoto.2016.366810.1001/jamaoto.2016.3668 ↗
8. 10.1038/s41598-017-04750-110.1038/s41598-017-04750-1 ↗
9. 10.1002/1521-4184(200208)335:6<262::AID-ARDP262>3.0.CO;2-Y10.1002/1521-4184(200208)335:6<262::AID-ARDP262>3.0.CO;2-Y ↗
10. 10.1155/2016/274836710.1155/2016/2748367 ↗
11. 10.1159/00048826410.1159/000488264 ↗
12. Gao C, Liang C, Nie Z, et al. Alkannin inhibits growth and invasion of glioma cells C6 through IQGAP/mTOR signal pathway. Int J Clin Exp Med. 2015;8:5287–5294.
13. 10.1002/ptr.468010.1002/ptr.4680 ↗
14. 10.1016/j.intimp.2014.05.02610.1016/j.intimp.2014.05.026 ↗
15. 10.1038/nrg.2016.13410.1038/nrg.2016.134 ↗
16. 10.3402/jev.v5.3129210.3402/jev.v5.31292 ↗
17. 10.1038/ncb202410.1038/ncb2024 ↗
18. 10.12659/MSM.89568310.12659/MSM.895683 ↗
19. 10.1016/j.oraloncology.2008.02.00410.1016/j.oraloncology.2008.02.004 ↗
20. 10.1007/s11010-011-0898-y10.1007/s11010-011-0898-y ↗
21. 10.1007/s00432-012-1152-z10.1007/s00432-012-1152-z ↗
22. 10.3892/ol.2016.420710.3892/ol.2016.4207 ↗
23. 10.1371/journal.pone.015546910.1371/journal.pone.0155469 ↗
24. Yang JG, Lu R, Ye XJ, et al. Icaritin reduces oral squamous cell carcinoma progression via the inhibition of STAT3 signaling. Int J Mol Sci. 2017;18:132 (1-15).
25. 10.2147/OTT.S16450310.2147/OTT.S164503 ↗
26. 10.1016/j.joms.2015.09.03810.1016/j.joms.2015.09.038 ↗
27. 10.1007/s13277-015-4246-910.1007/s13277-015-4246-9 ↗
28. 10.1074/jbc.M112.42573610.1074/jbc.M112.425736 ↗
29. 10.1073/pnas.131014411010.1073/pnas.1310144110 ↗
30. 10.1016/j.oraloncology.2011.11.00610.1016/j.oraloncology.2011.11.006 ↗
31. 10.1016/j.bbrc.2014.10.12210.1016/j.bbrc.2014.10.122 ↗
32. 10.1038/s41598-017-01960-510.1038/s41598-017-01960-5 ↗
33. 10.1038/sj.bjc.660452110.1038/sj.bjc.6604521 ↗
34. 10.1007/s13277-016-5362-x10.1007/s13277-016-5362-x ↗
35. 10.3892/ijmm.2013.135810.3892/ijmm.2013.1358 ↗
36. 10.1016/j.neo.2015.01.00310.1016/j.neo.2015.01.003 ↗
37. 10.1177/17246008060210030710.1177/172460080602100307 ↗
38. Klosek SK, Nakashiro K, Hara S, et al. Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma. Oncol Rep. 2008;20:873–878.
39. 10.1016/j.biopha.2016.11.08410.1016/j.biopha.2016.11.084 ↗
40. Li P, Xiao LY, Tan H. Muc-1 promotes migration and invasion of oral squamous cell carcinoma cells via PI3K-Akt signaling. Int J Clin Exp Pathol. 2015;8:10365–10374.